Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent studies in retinitis pigmentosa showed mixed results for gene and optogenetic therapies. UGX-201 and MCO-010 were associated with visual acuity improvements, while AAV8.hPDE6A showed no significant functional gains at 1 year.
Early clinical studies highlighted nonhormonal male contraception candidates YCT-529 and ADAM. YCT-529 showed favorable phase 1a safety, while ADAM reported mild transient effects and durability up to 24 months.
Hearings in Benjamin Netanyahu’s criminal trial were canceled this week after the death of a close family member of one presiding judge. The case remains in cross-examination in Case 4000, and Netanyahu is not expected back on the stand before next week.
A pooled analysis of five randomized trials found intranasal esketamine improved MADRS scores in adults with TRD in both sexes. Females showed greater improvement and higher odds of treatment-response toward trial end.
Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
NIH said it will no longer classify BESH studies as clinical trials for grant applications due on or after May 25, 2026. The change removes ClinicalTrials.gov registration and reporting requirements for those studies.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
The S&P 500 has swung to a loss for the year as volatility, geopolitical strains and profit-taking weigh on large-cap stocks. SanDisk, Venture Global and Moderna were among the top gainers.
Studies found gut microbiome changes linked to Parkinson’s risk before symptoms and hair mineral differences in diagnosed patients. Both findings need larger follow-up studies.
Western Australia will invest more than $5 million in the 2026-27 State Budget to support regional air routes. The package includes $3.8 million for the Inter-Regional Flight Network and more than $1.3 million for two Kimberley services.
DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.
Sino Biopharmaceutical won Chinese approval for a new indication for benmelstobart as maintenance therapy in unresectable stage III NSCLC after chemoradiotherapy. Phase III R-ALPS data showed significantly prolonged progression-free survival versus placebo and a manageable safety profile.
Two studies reported mitochondrial mechanisms linked to diabetic wound repair, including targeted mitochondrial transplantation and the circular RNA circMTRNR2. The findings showed improved healing in experimental models and identified potential targets for chronic wound treatment.
Tracy Beth Høeg said in her first address to staff that she will scrutinize antidepressants and RSV products used to protect babies. She said she is prioritizing the health of women and babies.
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
Thrive Capital has raised more than $10 billion in its largest fund ever. The fundraising was heavily oversubscribed and the cash influx was double the size of its last fund.
Police in Karachi, Kentucky and Indiana arrested three suspects in separate drug investigations involving alleged trafficking in Ice, methamphetamine and cocaine. One case involved a controlled purchase, while another led to the seizure of nearly 60 grams of cocaine and a firearm.
